|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 13, Num. 1, 2008, pp. 16-19
|
Middle East Fertility Society Journal, Vol.
13, No. 1, 2008, pp. 16-19
DEBATE
The
current role of metformin in the management of infertility
Prof. Dr. Abdelhamid Attia
Prof. of Obstetrics & Gynecology, Cairo University, President of the Arab Federation of
Evidence-Based Medicine, amattia@link.net
Code Number: mf08003
In 1935, Drs Irving
Stein and Michael Leventhal were the first to report the association of
amenorrhoea, hirsutism, obesity, and infertility; a syndrome that is currently
known as the polycystic ovary syndrome (PCOS). The PCOS is considered one of
the commonest endocrinopathies that affect between 5 to 10 percent of women of
reproductive age (1). The syndrome is also the commonest cause of infertility
in women as it is estimated that between 15 to 20 percent of infertile women
suffer from anovulatory infertility due to PCOS. Although this syndrome has
been extensively studied for more than 70 years, its etiology, pathogenesis,
clinical presentations, diagnostic criteria, hence its management, are still
not clearly understood or universally approved.
Is there an accepted pathogenetic
pathway?
Although intraovarian
androgen excess is considered the direct cause of anovulation and the
polycystic appearance of the ovary; yet the etiological and pathogenetic
pathways of the PCOS are still controversial. A lot of mechanisms have been
proposed as etiological factors leading to PCOS. Some old theories were ovarian
congestion, ovarian dystrophy, thickened tunica albuginea and excessive
secretion of androgens by the adrenal gland. More recently many other
mechanisms have been implicated in the pathogenesis of PCOS such as abnormal
pituitary function, abnormal ovarian steroidogenesis, obesity, and insulin
resistance. However, the syndrome is currently seen as a complex genetic
disorder, similar to diabetes and metabolic syndrome, in which a variety of
predisposing genes interact with environmental factors to produce the disease
(2). The involved genes include genes regulating gonadotropin and steroid
biosynthesis and action (manifested by elevated LH), weight and energy
regulation (manifested by obesity), androgen biosynthesis and action
(manifested by ovarian hyperandrogenism), and insulin secretion and action
(manifested by hyperinsulinemia) (2). Environmental factors such as diet and
its association with obesity may also contribute to the development of the
syndrome.
What are the diagnostic criteria of PCOS
The
classic criteria for diagnosing PCOS described by Stein and Leventhal were the
association of infertility, obesity, hirsutism, and amenorrhoea (1). However,
since this classic description a myriad of symptoms and signs were attributed
to the syndrome such as menstrual irregularities ranging from amenorrhoea,
oligomenorrhoea, to normal cycles, and irregular menstruation, hyperandrogenic
manifestations in the form of acne, hirsutism, oily skin, and alopecia, High
LH/FSH ratio, obesity either generalized or central adiposity, infertility,
recurrent pregnancy loss, and polycystic appearance of the ovaries by
ultrasound.
In 1990 National
Institutes of Health Conference on PCOS; the presence of three criteria was
proposed, at minimum, to diagnose PCOS: a) oligo-ovulation or anovulation, b)
clinical or biochemical evidence of hyperandrogenism, and c) exclusion of other
causes of hyperandrogenism (3). These criteria also ignored the
ultrasonographic appearance of the ovaries.
In 2003, The Rotterdam
criteria for diagnosing PCOS have been proposed by the ESHRE/ASRM consensus
workshop group (4) in which any two out of three criteria are required to make
the diagnosis: a) oligo-ovulation and/or anovulation, b) clinical and/or biochemical signs of hyperandrogenism, c) polycystic ovaries by ultrasound.
This classification included two different groups of patients; patients with
polycystic ovaries and hyperandrogenism but with normal ovarian function, and
patients with oligo- or anovulation and polycystic ovaries but with no evidence
of hyperandrogenism. The two groups might have different etiologies, and
prognosis. Thus, the Rotterdam revised criteria are not universally accepted.
In
2006, the Androgen Excess Society proposed the presence of the following 3
diagnostic criteria for the diagnosis of PCOS: a) clinical and/or biochemical
hyperandrogenism, b) ovarian dysfunction in the form of oligo-anovulation
and/or polycystic ovary appearance), and c) exclusion of other causes of
androgen excess or ovulatory disorders.
The
running controversy is not settled yet and the diagnosis of PCOS remains
controversial.
Insulin resistance and the PCOS
Insulin
resistance is a state in which a given concentration of insulin is associated
with a subnormal glucose response (6). Resistance to endogenous insulin is characterized
by a high fasting insulin levels while blood glucose levels are normal or high.
There is a strong association between PCOS and insulin resistance. It was found
that around 31% (7) to 40% (8) of reproductive age women with PCOS have an
impaired glucose tolerance (IGT) and 7.5% (7) to 10% (8) of them have type 2
diabetes. Moreover the annual conversion rate from normal to IGT among women
with PCOS was found to be 16% (9). Hyperinsulinemia acts by increasing androgen
levels both directly by stimulating androgen synthesis in the ovarian theca
cells and indirectly by suppressing the hepatic production of sex hormone
binding globulin. Measures to reduce insulin resistance as weight loss,
metformin, or thiazolidinedione use are associated with decreased androgen
levels in women with PCOS. This response formed a base for the use of metformin
in PCOS.
Metformin: to be used or not to be used?
Both insulin resistance
(manifested as hyperinsulinemia) and increased LH production increase
intraovarian as well as peripheral androgen secretion leading to anovulation.
There is no consensus among endocrinologists
on how to evaluate patients for insulin resistance. Tests to detect insulin
resistance are used in scientific research but they are impractical for routine
clinical use. Metformin acts by combating hyperinsulinemia leading to decreased
androgen levels. The insulin lowering effect of metformin is mainly obtained by
its ability to decrease glucose production by the liver and its absorption from
the intestine reducing the need for insulin secretion by the pancreas (10).
Metformin has also an anti-lipolytic effect reducing circulating free fatty
acids and hence gluconeogenesis (11). Unlike sulfonylureas used also to treat
hyperglycemia, metformin does not lower blood glucose to hypoglycemic levels
either in normal or in diabetic patients.
Metformin is a rather
safe drug. Its side effects are diarrhea, nausea, vomiting, flatulence,
indigestion, and abdominal discomfort. Its recommended dose is 1500 2550 mg (500
- 850 mg bid or tds) preferably with meals to reduce its GIT side effects. Thus
metformin use in the treatment of infertility is mainly empirical based on its
high margin of safety. To date Metformin is FDA approved only for use in
non-insulin dependant diabetes but its use in the treatment of PCOS is
off-label.
The use of metformin
either alone or combined with clomiphene citrate (CC) for the treatment of
anovulatory infertility due to PCOS has been widely studied. Although many
studies showed an evident benefit for the use of metformin in infertility
treatment, yet many of the studies were either uncontrolled, had small numbers
of participants or did not have allocation concealment. Also the controversy in
the diagnostic criteria of PCOS was reflected on the selection of participants
to various studies rendering these studies with heterogeneous populations,
thus; combining their results to reach a conclusion is very difficult to accept
if not impossible.
A Cochrane systematic
review published in 2003 revised 24 randomized controlled trials that studied
the effect of insulin sensitizers mainly metformin in the treatment of PCOS
(12). Fifteen studies were judged valid to be included in the review. For
infertility treatment; pregnancy is the patient-oriented outcome that matters
and that should be looked for. Comparing metformin alone to placebo in 5
studies showed no significant increase in the pregnancy rate in the metformin
treated patients. Five trials only compared the use of metformin plus CC versus
CC alone and their analysis showed a significantly higher clinical pregnancy
rate in favor of adding metformin to CC (Peto OR 4.40, p=0.0003, 95% CI 1.96 to
9.85). However, 4 of the 5 studies included patients who failed to ovulate on
CC alone (CC-resistant) and none of the studies considered pregnancy as the
primary outcome. Also the total number of participants in the 5 studies was
small (219 patients), heterogeneity in the inclusion criteria, as well as the
possibility of publication bias limits confidence in this analysis.
In 2006 and 2007, 2
large RCTs have been published that evaluated the use of metformin in the
treatment of infertility due to PCOS. What characterized the two studies is
that they had high validity, the number of participants in any of them was much
higher than the total number of participants in the 5 studies analyzed in the
2003 systematic review, their inclusion criteria matched those of the
ESHRE/ASRM 2003 consensus, all the patients were naive patients, other causes
of anovulation (or hyperandrogenism) as well as male factor were excluded, and
both studies reported pregnancy in their outcomes. The first study included 225
infertile women with chronic anovulation and PCO appearance by US who were
randomized into 2 groups to receive either CC plus metformin or CC plus placebo
for up to 6 months. The results showed a non significant difference in the
pregnancy and abortion rates between the two groups (13). The second study
included 626 infertile women with oligomenorrhoea and hyperandrogenism who were
randomized to receive CC plus placebo, extended-release metformin plus placebo,
or a combination of metformin and CC for up to 6 months. The results showed
that the live-birth rate was significantly higher (P<0.001) in the CC (22.5%)
and the CC plus metformin (26.8%) groups than in the metformin alone (7.2%)
group. However, there was no significant difference (P = 0.31) in the live
birth rate between the CC (22.5%) and the CC plus metformin (26.8%) groups
(14).
In conclusion
Current evidence
suggests that the use of metformin or the addition of metformin to CC therapy
does not increase the chances of pregnancy in infertile women with PCOS.
However, the lack of a universal agreement on the criteria of diagnosing PCOS
and the lack of a screening procedure for insulin resistance may contribute to
this failure. Thus, whether metformin would be helpful in a subgroup of
patients who show evidence of insulin resistance or not is not clear yet and
awaits further evidence.
REFERENCES
- Asuncion M, Calvo RM, San Millan
JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the
prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434.
- Goodarzi, MO, Azziz, R. Diagnosis, epidemiology,
and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol
Metab 2006; 20:193.
- Zawadski,
JK, Dunaif, A. Diagnostic criteria for polycystic ovary syndrome: Towards a
rational approach. In: Polycystic Ovary Syndrome, Dunaif, A, Givens, JR,
Haseltine, FP, Merriam, GE (Eds), (Series Ed: Hershman, SM), Current Issues in
Endocrinology and Metabolism, Blackwell Scientific Publications, Boston 1992. p.377.
- Revised
2003 consensus on diagnostic criteria and long-term health risks related to
polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.
- Azziz,
R, Carmina, E, Dewailly, D, et al. Positions statement: criteria for defining
polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an
Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91:4237.
- Moller,
DE, Flier, JS. Insulin resistance--mechanisms, syndromes, and implications. N
Engl J Med 1991; 325:938.
- Legro
RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type
2 diabetes mellitus and impaired glucose tolerance in polycystic ovary
syndrome: a prospective, controlled study in 254 affected women. J Clin
Endocrinol Metab. 1999; 84:165.
- Ehrmann
DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance
and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;
22:141.
- Legro
RS, Gnatuk CL, Kunselman AR, et al. Changes in glucose tolerance over time in
women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol
Metab. 2005; 90:3236.
- Bailey, CJ, Turner, RC.
Metformin. N Engl J Med 1996; 334:574.
- Patane, G, Piro,
S, Rabuazzo, AM, et al. Metformin
restores insulin secretion altered by chronic exposure to free fatty acids or
high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes
2000; 49:735.
- Lord JM, Flight IHK, Norman RJ. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone,
pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane
Database of Systematic Reviews 2003, Issue 2.
- Moll E, Bossuyt PM,
Korevaar JC, Lambalk CB, Van der Veen F. Effect of clomiphene citrate plus
metformin and clomiphene citrate plus placebo on induction of ovulation in
women with newly diagnosed polycystic ovary syndrome: randomized double blind
clinical trial.BMJ2006; 332:1485.
- Legro RS, Barnhart HX,
Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C,
McGovern PG, Cataldo NA et al. Clomiphene, metformin, or both for infertility
in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.
©Copyright 2008 - Middle East Fertility Society
|